ITHUF · iANTHUS CAPITAL HOLDINGS, INC.
Substantial doubt about the company's ability to continue as a going concern.
“While we believe that we have funding necessary for us to continue as a going concern, we may need to raise additional capital and there can be no assurance that such capital will be available to us on favorable terms, if at all. As such, these material circumstances cast substantial doubt on our ability to continue as a going concern for a period of no less than 12 months from the date of this report, and our unaudited interim condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $4.4M | Q2 2026 | — |
| EBITDA non-GAAP | $1.49M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) -14.42M
+4.71M Depreciation and amortization
+4.17M Interest expense, net
+7.03M Income tax expense (benefit)
= EBITDA 1.49M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ITHUF
this stock
iANTHUS CAPITAL HOLDINGS, INC.
|
$27.90M | -16.0% | -14.1% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$64.15B | +27.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$48.88B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$46.21B | +30.2% | +4.3% | 65.0 | 2.6% |
|
HLN
Haleon plc
|
$44.72B | -0.9% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Byrne Asset Management LLC
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ITHUF | -2.3% | -8.7% | -16.0% | +10.5% | -16.0% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -1.2% | -8.1% | -24.1% | +9.7% | -28.8% |